Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 21
Filter
Add more filters










Publication year range
1.
Vaccine ; 24(15): 2843-9, 2006 Apr 05.
Article in English | MEDLINE | ID: mdl-16494976

ABSTRACT

A retrospective review was conducted of yellow fever vaccination among laboratory workers receiving annual serologic assessment to determine the initial and long-term response after boosting. Patients were divided into three groups based on pre-vaccination serology: Group 1, 1:10; Group 2, 1:20-1:40 and Group 3, >1:40. The percent with > or = four-fold increase in titers after booster vaccination were: 78% (646/829, Group 1), 65% (79/121, Group 2) and 10% (8/79, Group 3) (p<0.0001). The median times to titer failure (<1:40) were 798 days (Group 1), 3340 days (Group 2) and 7709 days (Group 3) (p<0.0001). Pre-vaccination serology influenced the initial and long-term response to yellow fever booster vaccination.


Subject(s)
Antibodies, Viral/blood , Immunization, Secondary , Neutralization Tests , Yellow Fever Vaccine/immunology , Adult , Female , Humans , Male , Medical Laboratory Personnel , Middle Aged , Military Personnel , Retrospective Studies , Time Factors , United States , Yellow Fever Vaccine/administration & dosage
2.
Bull World Health Organ ; 74(6): 591-7, 1996.
Article in English | MEDLINE | ID: mdl-9060219

ABSTRACT

A total of 120 semi-immune adult male malaria patients from an area of multidrug-resistant Plasmodium falciparum malaria were hospitalized for 42 days in Medellin, Colombia (an area of no malaria transmission), and treated with halofantrine in a double-blind, randomized, prospective clinical trial according to five different treatment schedules. Each patient was assigned to one of the following halofantrine schedules: I, one dose of 1000 mg; II, three doses of 500 mg; III, two doses of 500 mg; IV, three doses of 250 mg; and V, one dose of 750 mg. Best results (75% cure rate) were obtained with schedule II, although there was no statistically significant difference compared with the other schedules. A total of 46 patients experienced recrudescent malaria. Drug levels in plasma 72 hours after beginning treatment showed no statistically significant difference between relapsing and cured patients. Side-effects (mainly gastrointestinal) were uncommon and mild. Cardiotoxicity was studied by electrocardiogram. A mean prolongation of 28.5 ms (6.6 +/- 6.3% increase from baseline) was observed in the Q-Tc interval on day 1 of the trial.


Subject(s)
Antimalarials/therapeutic use , Malaria, Falciparum/drug therapy , Phenanthrenes/therapeutic use , Adolescent , Adult , Aged , Antimalarials/administration & dosage , Antimalarials/adverse effects , Child , Colombia , Double-Blind Method , Drug Administration Schedule , Heart/drug effects , Humans , Male , Middle Aged , Phenanthrenes/administration & dosage , Phenanthrenes/adverse effects , Recurrence
4.
Ann Intern Med ; 120(4): 294-9, 1994 Feb 15.
Article in English | MEDLINE | ID: mdl-8291822

ABSTRACT

OBJECTIVE: To determine whether doxycycline, 100 mg administered as a single daily oral dose, is effective as a causal prophylactic agent, an agent active against the pre-erythrocytic liver stage of Plasmodium falciparum malaria parasites, in healthy nonimmune persons. If effective, the recommendation by the Centers for Disease Control and Prevention (CDC) that doxycycline be continued for 4 weeks after returning from malaria-endemic areas could be shortened to 1 week. DESIGN: Randomized, double-blind, placebo-controlled trial. SETTING: Medical ward at the U.S. Army Research Institute of Infectious Diseases, Fort Detrick, Maryland. PARTICIPANTS: 18 nonimmune, healthy, adult male volunteers, age 21.7 +/- 2.9 (SD) years, were enrolled in two groups, one of 8 persons and one of 10 persons. Six participants in the first group and 7 in the second group received doxycycline. The remaining participants received placebo. Two volunteers were dropped from the study, leaving 16 participants for analysis. INTERVENTION: Each participant received doxycycline, 100 mg, or placebo in a single daily oral dose starting 3 days before exposure to P. falciparum-infected mosquitoes and ending 6 days after exposure. MEASUREMENTS: Monitoring for parasitemia, plasma doxycycline concentrations, and mosquitoes' salivary-gland sporozoite grade. RESULTS: 6 of 6 (100% [95% Cl, 54% to 100%]) participants on doxycycline in the first group and 2 of 6 (33% [Cl, 4% to 78%]) in the second group were protected from malaria. No differences were found between protected and nonprotected participants in the doxycycline elimination half-life (T1/2) (20.8 +/- 5.0 h compared with 21.9 +/- 5.2 h), the steady-state average plasma concentration (1626 +/- 469 ng/mL compared with 1698 +/- 651 ng/mL), or other pharmacokinetic parameter estimates. The mean mosquito salivary-gland sporozoite grade was significantly higher (P = 0.02) in protected (3.5 +/- 0.3) than in nonprotected persons (3.1 +/- 0.1). Overall, 8 of 12 persons on doxycycline were protected from malaria, yielding a causal prophylactic efficacy rate of 67% (Cl, 35% to 90%). CONCLUSIONS: A dosing regimen of doxycycline, 100 mg once daily, administered as a causal prophylactic agent against P. falciparum malaria in healthy, nonimmune volunteers, had an unacceptably high failure rate. Therefore, the CDC recommendation that doxycycline should be taken daily starting 1 to 2 days before travel, during travel, and for 4 weeks after travel should still be followed.


Subject(s)
Doxycycline/administration & dosage , Malaria, Falciparum/prevention & control , Administration, Oral , Adult , Animals , Double-Blind Method , Doxycycline/pharmacokinetics , Drug Administration Schedule , Humans , Immunocompetence , Male
5.
Am J Trop Med Hyg ; 47(1): 108-11, 1992 Jul.
Article in English | MEDLINE | ID: mdl-1636876

ABSTRACT

Reports of deteriorating quinine efficacy prompted us to investigate the ability of quinine-tetracycline to clear parasites and fever from patients with multiple drug-resistant Plasmodium falciparum infections. Past and present treatment results were compared at two study sites along the Thai-Cambodian border. In northeastern Thailand, quinine-tetracycline cleared parasites more quickly in 1990 than in 1987 (mean 3.4 and 4.0 days, respectively; P = 0.006). In southeastern Thailand, there were no significant differences between 1990 (n = 26) and 1981-1983 (n = 42) in the time taken to clear either parasites (median 96 and 93 hr, respectively; P = 0.35) or fever (mean 74 and 66 hr, respectively; P = 0.30). In vitro drug sensitivity testing revealed a two-fold decrease in susceptibility to quinine between 1983 and 1990 in isolates from the southeastern Thai-Cambodian border (mean inhibitory concentration 166 ng/ml and 320 ng/ml, respectively; P less than 0.001). We conclude that oral quinine-tetracycline continues to reliably clear parasites and fever from falciparum malaria patients infected in eastern Thailand. Periodic re-evaluations are warranted, however, since the decrease in vitro susceptibility to quinine may be followed by an in vivo decay in the treatment response.


Subject(s)
Malaria, Falciparum/drug therapy , Plasmodium falciparum/drug effects , Quinine/therapeutic use , Tetracycline/therapeutic use , Adult , Animals , Drug Resistance , Drug Therapy, Combination , Humans , Male , Military Personnel , Prospective Studies , Quinine/pharmacology , Tetracycline/pharmacology , Thailand
6.
Article in English | MEDLINE | ID: mdl-1948277

ABSTRACT

From July 1983 to March 1984 a randomized double blind prophylactic trial in Thai gem miners working across the border in Cambodia was conducted to determine the prophylactic efficacy of 3 drug regimens against P. falciparum and P. vivax malaria along the Thai-Cambodian border. Gem miners have a high incidence of malaria. Maximum duration of individual participation was 14 weeks. Of 334 participants in this study who were seen every 2 weeks, 145 received mefloquine 500 mg fortnightly, 112 received chloroquine 300 mg base weekly plus Fansidar (1000 mg sulfadoxine and 50 mg pyrimethamine) fortnightly and 77 received chloroquine as 300 mg base weekly. The significant reduction of vivax malaria in study subjects (compared to background incidence) implied good compliance with self administration of chloroquine in the intervening weeks between scheduled appointments. The attack rate in each prophylactic regimen was 2188 cases/1000/year with mefloquine, 8338 cases/1000/year with chloroquine-Fansidar and 10,207 cases/1000/year receiving chloroquine alone. There was a 79% prophylactic efficacy for mefloquine and 18% efficacy for the chloroquine plus Fansidar regimen compared to chloroquine. Using life table analysis, 56% of the mefloquine group, 6% of the chloroquine-Fansidar group and 4% of the chloroquine group were malaria free at the end of the 14 weeks study. The chloroquine plus sulfadoxine-pyrimethamine regimen prescribed for prophylaxis is no longer effective for multidrug resistant strains of P. falciparum in the study area. This study also seriously questions the efficacy of mefloquine prophylaxis.


Subject(s)
Antimalarials/therapeutic use , Chloroquine/therapeutic use , Malaria/prevention & control , Mefloquine/therapeutic use , Pyrimethamine/therapeutic use , Sulfadoxine/therapeutic use , Adolescent , Adult , Aged , Analysis of Variance , Animals , Cambodia , Confidence Intervals , Double-Blind Method , Drug Combinations , Drug Therapy, Combination , Humans , Malaria, Falciparum/prevention & control , Malaria, Vivax/prevention & control , Male , Middle Aged , Survival Analysis , Thailand
7.
Clin Pharmacol Ther ; 48(4): 399-409, 1990 Oct.
Article in English | MEDLINE | ID: mdl-2225700

ABSTRACT

Mefloquine pharmacokinetics were compared in a randomized clinical trial in Thailand among patients with malaria and healthy volunteers. A single oral dose of 1500 mg mefloquine hydrochloride was administered to 11 patients and 5 volunteers and 750 mg was given to 16 patients and 5 volunteers. Efficacy was 82% for 1500 mg and 63% for 750 mg. In cured patients taking 750 mg mefloquine, peak plasma drug concentration (Cmax) and area under the plasma concentration-time curve (AUC) were significantly greater than in the patients for whom treatment failed (p less than 0.0005 and p less than 0.01, respectively), and plasma mefloquine levels were significantly higher from 8 hours to 18 days after treatment. Mefloquine AUC was reduced and variable in the presence of diarrhea. Compared with noninfected volunteers, clinically ill patients displayed a delayed time to reach peak concentration (p less than 0.01) and significantly higher mefloquine plasma levels in the first 2 days after administration of either the 750 mg or the 1500 mg dose. Mefloquine AUC was similar in patients with malaria and healthy volunteers. Because plasma levels increased in temporal relationship with clinical illness, mefloquine volume of distribution or clearance (or both) was reduced during the acute phase of illness.


Subject(s)
Malaria/drug therapy , Mefloquine/pharmacokinetics , Plasmodium falciparum , Acute Disease , Administration, Oral , Adolescent , Adult , Animals , Drug Tolerance , Humans , Malaria/blood , Male , Mefloquine/administration & dosage , Mefloquine/adverse effects , Mefloquine/blood , Reference Values
8.
Am J Trop Med Hyg ; 40(1): 7-11, 1989 Jan.
Article in English | MEDLINE | ID: mdl-2644858

ABSTRACT

The antimalarial activities of amodiaquine, the desethyl metabolite of amodiaquine, chloroquine, and mefloquine were evaluated against 35 field isolates of Plasmodium falciparum collected from eastern Thailand, October-December 1985, to define patterns of cross-resistance among these compounds. The assay system was based on the in vitro inhibition of schizont maturation. The parasites were generally sensitive to mefloquine (mean 50%-inhibitory concentrations = 9.98 nM) and highly resistant to chloroquine (IC50 = 313 nM). The mean in vitro activity of desethylamodiaquine (67.5 nM) was approximately 3.5 times lower than that of amodiaquine (18.2 nM). There was a significant rank-order correlation between the IC50S of desethylamodiaquine and chloroquine, but not between amodiaquine and chloroquine, which suggests that the apparent cross-resistance between chloroquine and amodiaquine observed in clinical studies may be more closely related to the cross-resistance between chloroquine and the metabolite rather than between chloroquine and the parent compound. Isolates with IC50 values of amodiaquine greater than 20 nM demonstrated a high degree of correlation with values of desethylamodiaquine; however, it was not possible to accurately predict the sensitivity to desethylamodiaquine of isolates which had IC50 values of amodiaquine of less than 20 nM.


Subject(s)
Amodiaquine/pharmacology , Chloroquine/pharmacology , Plasmodium falciparum/drug effects , Amodiaquine/analogs & derivatives , Animals , Antimalarials/pharmacology , Drug Resistance , Mefloquine , Quinolines/pharmacology , Thailand
9.
Am J Trop Med Hyg ; 38(1): 24-9, 1988 Jan.
Article in English | MEDLINE | ID: mdl-3277460

ABSTRACT

Pyronaridine, a 9-substituted 1-aza-acridine, was assayed for in vitro activity against clinical and field isolates as well as characterized clones of Plasmodium falciparum. The in vitro antimalarial activity of pyronaridine was compared to activities of standard antimalarials against multidrug-resistant isolates of P. falciparum from eastern and northern Thailand using an assay based on the inhibition of schizont maturation. Isolates from eastern Thailand (n = 30) were susceptible to pyronaridine (IC50 8.40 nM), mefloquine (IC50 6.97 nM), and amodiaquine (IC50 12.7 nM) and resistant to chloroquine (IC50 361 nM), quinine (IC50 388 nM), and pyrimethamine (IC50 11,800 nM). The isolates from northern Thailand (n = 7) showed no statistical difference in susceptibility to pyronaridine (IC50 10.1 nM), amodiaquine (IC50 7.29 nM), and mefloquine (IC50 5.48 nM); however, isolates were significantly more susceptible to chloroquine (IC50 167 nM), quinine (IC50 248 nM), and pyrimethamine (IC50 1,980 nM). These data suggest a lack of cross-resistance between pyronaridine and either chloroquine, quinine, or pyrimethamine. Using the same assay system the in vitro activity of pyronaridine was evaluated against isolates from treatment failures of mefloquine or enpiroline from eastern Thailand. The IC50 values for mefloquine against five recrudescent isolates were significantly higher (IC50 16.4 nM) than the field isolates collected from the same region (IC50 6.97 nM); however, there was no significant difference in the pyronaridine susceptibility between the isolates from the field study (IC50 8.89 nM) and the isolates from the treatment failures (IC50 8.40 nM). These observations suggest a lack of cross-resistance to mefloquine following treatment failure with either mefloquine or enpiroline.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Antimalarials/pharmacology , Naphthyridines/pharmacology , Plasmodium falciparum/drug effects , Amodiaquine/pharmacology , Animals , Chemical Phenomena , Chemistry , Chloroquine/pharmacology , Drug Resistance , Humans , Mefloquine , Pyrimethamine/pharmacology , Quinine/pharmacology , Quinolines/pharmacology , Thailand
10.
Bull World Health Organ ; 66(2): 227-35, 1988.
Article in English | MEDLINE | ID: mdl-3293828

ABSTRACT

Halofantrine (WR 171,669) hydrochloride was administered orally to 82 patients infected with Plasmodium falciparum malaria on the Thai-Kampuchean border between June 1982 and December 1983 in a randomized double-blind treatment trial which compared the efficacy of halofantrine with that of mefloquine. Halofantrine was curative with oral treatment on a single day in 65% of patients (13/20) who received 1000 mg followed 6 hours later by an additional 500 mg, and in 88% of patients (53/60) who received 500 mg every 6 hours for 3 doses. Mefloquine was curative in 88% of patients (22/25) given a single oral dose of 1000 mg and in 97% of patients (38/39) given a single oral dose of 1500 mg. The difference in cure rates between the 3-dose halofantrine regimen and either of the mefloquine regimens was not significant. The mean parasite clearance time for all regimens ranged from 75 to 84 hours. The mean fever clearance time for all four treatment groups was in the range 50-60 hours, with no significant differences between groups. Post-dosing side-effects in patients treated with halofantrine consisted of nausea, vomiting, abdominal pain and diarrhoea and were not significantly different from those treated with mefloquine. Halofantrine therefore appeared to be of comparable efficacy to mefloquine in the treatment of multidrug-resistant P. falciparum malaria.


Subject(s)
Antimalarials/therapeutic use , Malaria/drug therapy , Phenanthrenes/therapeutic use , Adult , Clinical Trials as Topic , Double-Blind Method , Drug Administration Schedule , Humans , Male , Mefloquine , Middle Aged , Phenanthrenes/administration & dosage , Phenanthrenes/adverse effects , Quinolines/administration & dosage , Quinolines/therapeutic use , Random Allocation
12.
J Clin Microbiol ; 25(6): 1002-8, 1987 Jun.
Article in English | MEDLINE | ID: mdl-2439533

ABSTRACT

Antibodies that reacted with a candidate sporozoite vaccine antigen (R32tet32) were found in 20 of 21 patients treated for acute infection with Plasmodium falciparum and monitored longitudinally over 67 days. R32tet32 contains 32 tandem copies of a tetrapeptide sequence that constitutes the immunodominant epitope of the circumsporozoite surface protein. The magnitude of the antibody response varied considerably among individuals and appeared to be independent of the number of previous clinical infections. Recrudescence of infection or infection with Plasmodium vivax had no demonstrable effect on antibody levels, although reinfection with P. falciparum produced a rapid rise in antibody titer. Antibody levels were observed to decline rapidly after treatment of clinical infection with mefloquine. The apparent antibody half-life was 27 days, which is comparable to the half-life of circulating immunoglobulin G in humans. The data suggest that antisporozoite antibody production ceased on about day 4 after treatment of acute infection. A similar pattern of response was observed for antibodies against the erythrocytic forms of the parasite. The cessation of antibody synthesis was interpreted as being due to immunosuppression induced by the presence of intraerythrocytic parasites and may explain in part why protective immunity is poorly developed in natural malaria infections.


Subject(s)
Antigens, Protozoan/immunology , Malaria/immunology , Plasmodium falciparum/immunology , Vaccines/immunology , Acute Disease , Adolescent , Adult , Antibody Formation , Enzyme-Linked Immunosorbent Assay , Epitopes/immunology , Fluorescent Antibody Technique , Humans , Longitudinal Studies , Malaria/drug therapy , Male , Mefloquine , Quinolines/therapeutic use
13.
Lancet ; 1(8543): 1161-4, 1987 May 23.
Article in English | MEDLINE | ID: mdl-2883488

ABSTRACT

188 schoolchildren aged 10-15 living in a malaria endemic area along the Thai-Burmese border were matched for age, splenomegaly, and weight and were then randomly assigned to receive either doxycycline (adult equivalent of 100 mg daily) or chloroquine (adult equivalent of 300 mg base weekly). All drugs were administered by the investigators and blood smears were done weekly. In 95 subjects taking doxycycline for 597 man-weeks there were 5 cases of falciparum malaria and in the 93 controls taking chloroquine for 488 man-weeks there were 31. Doxycycline was more effective than chloroquine in the prevention of falciparum malaria infections (p less than 0.0001). The doxycycline group did not have significantly more side-effects than the chloroquine group.


Subject(s)
Doxycycline/therapeutic use , Malaria/prevention & control , Adolescent , Child , Chloroquine/therapeutic use , Clinical Trials as Topic , Doxycycline/administration & dosage , Humans , Malaria/epidemiology , Plasmodium falciparum , Plasmodium vivax , Random Allocation , Refugees , Thailand
14.
Am J Trop Med Hyg ; 34(6): 1022-7, 1985 Nov.
Article in English | MEDLINE | ID: mdl-3914841

ABSTRACT

Resistance to mefloquine in Plasmodium falciparum has begun to occur along the border of Thailand and Kampuchea. As a means of assessing the natural occurrence of mefloquine resistance, the admission and post-treatment parasite isolates from a mefloquine treatment failure were cloned and characterized. Clones from the admission isolate were susceptible to mefloquine in vitro (ID50 of 3.4 [2-5], G [95% CI] ng/ml) and showed a mixture of isozyme types for glucose phosphate isomerase (GPI types I and II). The post-treatment clones were resistant to mefloquine in vitro (ID50 of 17.3 [13-23] ng/ml) with only one isozyme (GPI type I) detected. These observations suggest that under mefloquine pressure a resistant parasite population was selected in the patient, indicating that the potential for mefloquine resistance already exists in the indigenous P. falciparum gene pool. In addition, the mefloquine-resistant clones showed decreased susceptibility in vitro to halofantrine suggesting possible cross-resistance to this new antimalarial drug currently under development.


Subject(s)
Antimalarials/pharmacology , Plasmodium falciparum/drug effects , Quinolines/pharmacology , Adult , Animals , Clone Cells , Drug Resistance , Glucose-6-Phosphate Isomerase/analysis , Humans , Isoenzymes/analysis , Malaria/drug therapy , Malaria/parasitology , Male , Mefloquine , Phenanthrenes/pharmacology , Plasmodium falciparum/classification , Plasmodium falciparum/cytology , Plasmodium falciparum/enzymology , Quinolines/therapeutic use , Thailand
15.
Am J Trop Med Hyg ; 34(2): 228-35, 1985 Mar.
Article in English | MEDLINE | ID: mdl-3885770

ABSTRACT

Antimalarial activity of chloroquine, quinine, mefloquine and halofantrine against 33 strains of P. falciparum isolated from naturally acquired malaria infections in Thailand was determined using a radioisotope microdilution method. A microtitration procedure was used to test isolates of P. falciparum against the 4 drugs simultaneously. The mean ID50 for chloroquine and quinine reflected known resistance to those drugs in Thailand. The mean ID50 for mefloquine and halofantrine showed susceptibility to these drugs. Four isolates of P. falciparum however had markedly decreased susceptibility to mefloquine (ID50 greater than 15 ng/ml); one case of which was confirmed as the first case of RII resistance for mefloquine in Thailand. Several parasite isolates were also observed to have decreased susceptibility to the new drug, halofantrine. These studies strongly recommend that in vitro testing be done in conjunction with field evaluation of new antimalarial drugs.


Subject(s)
Antimalarials/pharmacology , Malaria/drug therapy , Plasmodium falciparum/drug effects , Adult , Animals , Antimalarials/therapeutic use , Chloroquine/pharmacology , Drug Resistance, Microbial , Humans , Lethal Dose 50 , Malaria/parasitology , Male , Mefloquine , Microbial Sensitivity Tests , Phenanthrenes/pharmacology , Phenanthrenes/therapeutic use , Quinine/pharmacology , Quinolines/pharmacology , Quinolines/therapeutic use , Thailand
16.
Bull World Health Organ ; 63(4): 739-43, 1985.
Article in English | MEDLINE | ID: mdl-3910297

ABSTRACT

In eastern Thailand, falciparum malaria is highly chloroquine-resistant and is quickly becoming quinine-resistant. In the present study, ten patients with falciparum malaria were given large doses of erythromycin, combined with standard doses of chloroquine; the cure rate was 0 out of 10 (4 RIII failures, 6 RII failures). A further ten patients were given erythromycin with standard doses of quinine; 2 of the 10 patients were cured (8 RI failures). These regimens thus appear to have no appreciable effect against falciparum infections in eastern Thailand.


Subject(s)
Chloroquine/administration & dosage , Erythromycin/administration & dosage , Malaria/drug therapy , Quinine/administration & dosage , Adult , Drug Resistance, Microbial , Drug Therapy, Combination , Humans , Male , Plasmodium falciparum/drug effects , Thailand
18.
Am J Trop Med Hyg ; 33(5): 767-71, 1984 Sep.
Article in English | MEDLINE | ID: mdl-6385737

ABSTRACT

WR 180,409 (enpiroline) was administered to 22 non-immune subjects infected with the multi-drug resistant Vietnam Smith isolate of Plasmodium falciparum. It was curative in single day treatment regimens with a minimum curative dose of approximately 10 mg/kg body weight. At this dose level it was well tolerated and produced rapid clearance of parasitemia in every case.


Subject(s)
Malaria/drug therapy , Pyridines/therapeutic use , Adolescent , Adult , Drug Evaluation , Humans , Malaria/parasitology , Plasmodium falciparum/drug effects , Pyridines/administration & dosage , Pyridines/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...